Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2017-09-07 Proxy Solicitation & In…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于召开2017年第二次临时股东大会的提示性公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement about the convening of the 2017 second extraordinary general meeting (临时股东大会) of Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, voting procedures, agenda items to be discussed and voted on, registration details, and attachments such as proxy forms and voting instructions. There are no financial statements or financial performance data included. The document is not a report of voting results but a notice and instructions for the upcoming shareholder meeting. Therefore, it fits the category of a Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2017-09-07 Chinese
关于召开2017年第二次临时股东大会的通知公告
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice and announcement for the 2017 second extraordinary general meeting (临时股东大会) of Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, agenda items for shareholder voting, registration procedures, voting methods (including online voting), and attachments such as proxy forms and shareholder registration forms. The document does not contain financial statements or results but is focused on informing shareholders about the meeting and soliciting their votes on various corporate governance and capital structure proposals. This matches the definition of a Proxy Solicitation & Information Statement (PSI), which is material sent to shareholders to provide information and request votes for meetings. The document length is over 5,000 characters and contains detailed meeting and voting information, not just a brief announcement or a report publication notice. Therefore, the correct classification is PSI.
2017-08-30 Chinese
会计师事务所选聘制度（2017年8月）
Governance Information Classification · 95% confidence The document is titled '深圳华大基因股份有限公司 会计师事务所选聘制度' which translates to 'Shenzhen BGI Co., Ltd. Auditor Selection System'. It details the procedures, requirements, and governance related to the selection, appointment, and replacement of the company's accounting firm (auditor). It includes references to board and shareholder meeting approvals, audit committee roles, and regulatory compliance. The document is a policy or governance document about auditor selection rather than an audit report, annual report, or financial statement. It does not contain financial data or audit results but rather internal rules and procedures. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is 3456 characters, which is substantive and not a mere announcement or certification. Hence, the classification is CGR with high confidence.
2017-08-29 Chinese
独立董事关于关联交易的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions on related party transactions, referencing regulatory guidelines and company rules. It is not a full report, financial statement, or announcement of voting results. It is a governance-related document concerning board oversight and compliance with regulations on related party transactions. Therefore, it fits best under Board/Management Information (MANG), which covers announcements related to board activities and management decisions.
2017-08-29 Chinese
独立董事制度（2017年8月）
Governance Information Classification · 100% confidence The document is titled "深圳华大基因股份有限公司 独立董事制度" which translates to "Shenzhen BGI Genomics Co., Ltd. Independent Director System." It is a detailed policy document outlining the governance structure, qualifications, nomination, duties, and working conditions of independent directors at the company. The content focuses on governance rules, director responsibilities, and compliance with relevant laws and regulations. There is no financial data, earnings information, or report publication announcement. The document is a governance-related policy document, not a report or announcement of financial results or corporate actions. Therefore, the most appropriate classification is Governance Information (CGR).
2017-08-29 Chinese
关于增加2017年度预计日常关联交易额度的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by Shenzhen BGI Genomics Co., Ltd. regarding the increase in the 2017 estimated daily related party transaction quota. It details the related parties, the nature of transactions, pricing policies, and approvals by the board, supervisory committee, independent directors, and the sponsor institution. The content focuses on corporate governance and disclosure of related party transactions rather than financial results or comprehensive financial statements. It is not a full annual or interim report, audit report, earnings release, or any other financial report type. It is also not a regulatory filing or certification letter. The document is a formal announcement of a board-approved management decision related to related party transactions, which fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2017-08-29 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.